Holen Sie sich die Stockscreener-App
3.335
0.15%
0.005
Handel nachbörslich:
3.40
0.065
+1.95%
Schlusskurs vom Vortag:
$3.33
Offen:
$3.31
24-Stunden-Volumen:
62,120
Relative Volume:
0.78
Marktkapitalisierung:
$53.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1695
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
-3.05%
1M Leistung:
-0.45%
6M Leistung:
+23.06%
1J Leistung:
-3.05%
1-Tages-Spanne:
$3.28
$3.37
1-Wochen-Bereich:
$3.25
$3.55
52-Wochen-Spanne:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.335 | 52.94M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid at Lytham Partners: Strategic Insights on D-PLEX100 By Investing.com - Investing.com Australia
PolyPid to present phase 3 SHIELD II trial results at ACS congress - Investing.com
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - The Manila Times
PolyPid Ltd. Announces Presentation of Phase 3 SHIELD II Trial Results at 2025 ACS Clinical Congress - Quiver Quantitative
PolyPid to Present Its Positive Phase 3 SHIELD II Topline - GlobeNewswire
Price action breakdown for PolyPid Ltd.July 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
Tools to monitor PolyPid Ltd. recovery probabilityTrade Exit Summary & Capital Efficient Trading Techniques - newser.com
Will PolyPid Ltd. see short term momentumQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
PolyPid (NASDAQ:PYPD) & Cronos Group (NASDAQ:CRON) Head to Head Survey - Defense World
What analysts say about PolyPid Ltd stockVolume Analysis Techniques & Invest Smarter With Data-Driven Models - earlytimes.in
What drives PolyPid Ltd stock priceFibonacci Retracement Levels & Free Rapid Growing Investment Returns - earlytimes.in
PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus PT from Analysts - Defense World
PolyPid (NASDAQ:PYPD) Rating Increased to Hold at Wall Street Zen - MarketBeat
What to expect from PolyPid Ltd. in the next 30 days2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9%Time to Buy? - MarketBeat
PolyPid (NASDAQ:PYPD) Stock Price Up 2.9% – Time to Buy? - Defense World
Will a bounce in PolyPid Ltd. offer an exitBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - MarketBeat
Multi factor analysis applied to PolyPid Ltd.Exit Point & Verified High Yield Trade Plans - newser.com
Real time breakdown of PolyPid Ltd. stock performanceMarket Rally & AI Driven Price Predictions - newser.com
Does PolyPid Ltd. show high probability of reboundExit Point & Safe Entry Trade Signal Reports - newser.com
Strategies to average down on PolyPid Ltd.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
PolyPid completes Israeli Ministry of Health GMP inspection - MSN
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - MSN
Is PolyPid Ltd. forming a reversal patternRisk Management & Weekly High Return Stock Opportunities - newser.com
Decliners Report: Can PolyPid Ltd. ride the EV waveWeekly Market Report & Entry Point Strategy Guides - خودرو بانک
Applying Wyckoff theory to PolyPid Ltd. stockMarket Risk Summary & Proven Capital Preservation Methods - newser.com
Profit Review: Is now the right time to enter ATIIWJuly 2025 Pullbacks & Comprehensive Market Scan Insights - khodrobank.com
PolyPid Ltd. stock trendline breakdownJobs Report & Free Fast Entry Momentum Trade Alerts - newser.com
Using data models to predict PolyPid Ltd. stock movement2025 Top Decliners & Safe Swing Trade Setups - newser.com
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference - The Manila Times
PolyPid to Present at Lytham Partners Fall 2025 Investor - GlobeNewswire
Late-Stage Biopharma PolyPid Announces Double Conference Lineup: Lytham Partners and ROTH Healthcare - Stock Titan
Has PolyPid Ltd. found a price floorJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
PolyPid Completes Key GMP Inspection for D-PLEX100 Manufacturing Readiness - TipRanks
How to use Fibonacci retracement on PolyPid Ltd.Market Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Short Squeeze: Is PolyPid Ltd. forming a breakout patternQuarterly Earnings Report & Growth Focused Investment Plans - خودرو بانک
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection - MarketScreener
PolyPid Successfully Completes Israeli Ministry of Health - GlobeNewswire
Polypid clears Israeli health ministry GMP inspection, nears commercial manufacturing for D-PLEX - MarketScreener
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):